- Home
- OFS vs ATHA Comparison
OFS vs ATHA Comparison
Compare OFS & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OFS
- ATHA
- Stock Information
- Founded
- OFS 2001
- ATHA 2011
- Country
- OFS United States
- ATHA United States
- Employees
- OFS N/A
- ATHA N/A
- Industry
- OFS Finance/Investors Services
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- OFS Finance
- ATHA Health Care
- Exchange
- OFS Nasdaq
- ATHA Nasdaq
- Market Cap
- OFS 109.9M
- ATHA 93.5M
- IPO Year
- OFS 2012
- ATHA 2020
- Fundamental
- Price
- OFS $8.02
- ATHA $0.67
- Analyst Decision
- OFS
- ATHA Buy
- Analyst Count
- OFS 0
- ATHA 4
- Target Price
- OFS N/A
- ATHA $11.25
- AVG Volume (30 Days)
- OFS 46.0K
- ATHA 14.2M
- Earning Date
- OFS 10-31-2024
- ATHA 11-07-2024
- Dividend Yield
- OFS 16.96%
- ATHA N/A
- EPS Growth
- OFS N/A
- ATHA N/A
- EPS
- OFS N/A
- ATHA N/A
- Revenue
- OFS $49,799,000.00
- ATHA N/A
- Revenue This Year
- OFS N/A
- ATHA N/A
- Revenue Next Year
- OFS N/A
- ATHA N/A
- P/E Ratio
- OFS N/A
- ATHA N/A
- Revenue Growth
- OFS N/A
- ATHA N/A
- 52 Week Low
- OFS $7.75
- ATHA $0.41
- 52 Week High
- OFS $12.41
- ATHA $4.30
- Technical
- Relative Strength Index (RSI)
- OFS 43.72
- ATHA 51.78
- Support Level
- OFS $7.99
- ATHA $0.60
- Resistance Level
- OFS $8.09
- ATHA $0.83
- Average True Range (ATR)
- OFS 0.14
- ATHA 0.10
- MACD
- OFS 0.00
- ATHA 0.03
- Stochastic Oscillator
- OFS 42.00
- ATHA 61.60
About OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.